vs
Side-by-side financial comparison of BANK OF HAWAII CORP (BOH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
BANK OF HAWAII CORP is the larger business by last-quarter revenue ($192.3M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). BANK OF HAWAII CORP runs the higher net margin — 29.9% vs 1.6%, a 28.2% gap on every dollar of revenue. Over the past eight quarters, BANK OF HAWAII CORP's revenue compounded faster (10.7% CAGR vs -0.2%).
The Bank of Hawaii Corporation is an American regional commercial bank headquartered in Honolulu, Hawaii. It is Hawaii's second oldest bank and its largest locally owned bank in that the majority of the voting stockholders reside within the state. Bank of Hawaii has the most accounts, customers, branches, and ATMs of any financial institution in the state. The bank consists of four business segments: retail banking, commercial banking, investment services, and treasury. The bank is currently ...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BOH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $192.3M | $177.4M |
| Net Profit | $57.4M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 29.9% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | 30.6% | — |
| EPS (diluted) | $1.30 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $192.3M | $177.4M | ||
| Q4 25 | $189.6M | $196.9M | ||
| Q3 25 | $182.6M | $179.5M | ||
| Q2 25 | $174.5M | $181.1M | ||
| Q1 25 | $169.9M | $168.9M | ||
| Q4 24 | $163.2M | $187.3M | ||
| Q3 24 | $162.7M | $168.6M | ||
| Q2 24 | $156.9M | $178.0M |
| Q1 26 | $57.4M | $2.9M | ||
| Q4 25 | $60.9M | — | ||
| Q3 25 | $53.3M | $5.4M | ||
| Q2 25 | $47.6M | $-4.8M | ||
| Q1 25 | $44.0M | $4.8M | ||
| Q4 24 | $39.2M | — | ||
| Q3 24 | $40.4M | $-143.5M | ||
| Q2 24 | $34.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 40.9% | 1.2% | ||
| Q3 25 | 37.1% | 3.5% | ||
| Q2 25 | 34.6% | 4.7% | ||
| Q1 25 | 33.1% | 1.2% | ||
| Q4 24 | 31.6% | 13.2% | ||
| Q3 24 | 32.3% | -82.8% | ||
| Q2 24 | 28.9% | 15.9% |
| Q1 26 | 29.9% | 1.6% | ||
| Q4 25 | 32.1% | — | ||
| Q3 25 | 29.2% | 3.0% | ||
| Q2 25 | 27.3% | -2.7% | ||
| Q1 25 | 25.9% | 2.8% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 24.8% | -85.1% | ||
| Q2 24 | 21.7% | 10.6% |
| Q1 26 | $1.30 | $0.07 | ||
| Q4 25 | $1.40 | $0.05 | ||
| Q3 25 | $1.20 | $0.12 | ||
| Q2 25 | $1.06 | $-0.11 | ||
| Q1 25 | $0.97 | $0.10 | ||
| Q4 24 | $0.85 | $0.38 | ||
| Q3 24 | $0.93 | $-3.11 | ||
| Q2 24 | $0.81 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.9B | $653.9M |
| Total Assets | $23.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.3M | $144.3M | ||
| Q4 25 | $946.5M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | $935.2M | $493.6M | ||
| Q4 24 | $763.6M | $484.6M | ||
| Q3 24 | $1.3B | $453.8M | ||
| Q2 24 | $925.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $558.2M | $372.2M | ||
| Q3 25 | $558.2M | $376.7M | ||
| Q2 25 | $558.2M | $580.5M | ||
| Q1 25 | $558.3M | $583.4M | ||
| Q4 24 | $558.3M | $585.3M | ||
| Q3 24 | $558.3M | — | ||
| Q2 24 | $560.1M | — |
| Q1 26 | $1.9B | $653.9M | ||
| Q4 25 | $1.9B | $693.1M | ||
| Q3 25 | $1.8B | $727.2M | ||
| Q2 25 | $1.7B | $757.8M | ||
| Q1 25 | $1.7B | $798.5M | ||
| Q4 24 | $1.7B | $778.3M | ||
| Q3 24 | $1.7B | $749.6M | ||
| Q2 24 | $1.6B | $879.3M |
| Q1 26 | $23.9B | $1.2B | ||
| Q4 25 | $24.2B | $1.3B | ||
| Q3 25 | $24.0B | $1.3B | ||
| Q2 25 | $23.7B | $1.5B | ||
| Q1 25 | $23.9B | $1.6B | ||
| Q4 24 | $23.6B | $1.6B | ||
| Q3 24 | $23.8B | $1.5B | ||
| Q2 24 | $23.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | 0.54× | ||
| Q3 25 | 0.31× | 0.52× | ||
| Q2 25 | 0.32× | 0.77× | ||
| Q1 25 | 0.33× | 0.73× | ||
| Q4 24 | 0.33× | 0.75× | ||
| Q3 24 | 0.34× | — | ||
| Q2 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOH
| Net Interest Income | $151.0M | 79% |
| Noninterest Income | $41.3M | 21% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
